English court resumes Amgen cholesterol patent suit
23-10-2020
Kilpatrick Townsend hires litigation team from DLA Piper
19-10-2020
Casimiro PT / Shutterstock.com
Regeneron Pharmaceuticals is facing claims that its “antibody cocktail”, which was administered to President Donald Trump to treat his COVID-19 symptoms, was developed with the unauthorised use of a fluorescent protein.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Regeneron, Pfizer, COVID-19, protein, mNeonGreenprotein, Allele, biotechnology, royalties, mNeonGreen
